GOLDSTEIN JOSEPH L 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 25, 2024
Insider Transaction Report
Form 4
GOLDSTEIN JOSEPH L
Director
Transactions
- Sale
Common Stock
2024-01-23$950.00/sh−2,707$2,571,650→ 6,382 total - Exercise/Conversion
Common Stock
2024-01-23$625.60/sh+2,707$1,693,499→ 9,089 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-01-23−2,707→ 0 totalExercise: $625.60Exp: 2032-01-03→ Common Stock (2,707 underlying)
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023.
- [F2]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.